Third-party reimbursement issues during a phase I trial of interleukin-2.
Vogelzang
N J
NJ
Richards
J M
JM
D004341:Drug Evaluation / Q000191:economics*; D006801:Humans; D007349:Insurance, Health, Reimbursement; D007376:Interleukin-2 / Q000627:therapeutic use*; D014481:United States
D007376:Interleukin-2